Development of a modified gp130 ligand to treat obesity-induced insulin resistance

开发修饰的 gp130 配体来治疗肥胖引起的胰岛素抵抗

• 批准号: nhmrc : 1039502
• 负责人: Dr Tim Adams
• 金额: $ 29.24万
• 依托单位: Baker IDI Heart and Diabetes Institute
• 依托单位国家: 澳大利亚
• 项目类别: Development Grants
• 财政年份: 2012
• 资助国家: 澳大利亚
• 起止时间: 2012-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/development-modified-gp130-insulin-resistance/111288
• 关键词: Development; modified; gp130; ligand; treat

IC7 is a mixture of two naturally occurring proteins, CNTF and IL-6. These gp130 receptor ligands have been shown to have positive metabolic effects in humans, but individually they are not suitable for therapeutic use. IC7, the novel molecule this technology is based upon, is a combination of CNTF and IL-6 in a specific design to avoid the negative effects. Preliminary results suggest that IC7 has positive metabolic effects but further development is required to increase its effectiveness in treating insulin resistance and type 2 diabetes.

IC 7是两种天然存在的蛋白质CNTF和IL-6的混合物。这些gp 130受体配体已被证明在人体内具有积极的代谢作用，但单独使用它们不适合治疗用途。IC 7是该技术所基于的新型分子，是CNTF和IL-6的组合，以特定的设计来避免负面影响。初步结果表明，IC 7具有积极的代谢作用，但需要进一步开发以提高其治疗胰岛素抵抗和2型糖尿病的有效性。